Centessa Pharmaceuticals' Leadership Transition
In a significant step forward for Centessa Pharmaceuticals plc (Nasdaq: CNTA), the company has appointed Dr. Mario Alberto Accardi as its new Chief Executive Officer (CEO), effective January 1, 2026. This transition marks the culmination of a strategic evolution the company is undergoing, moving from a broad R&D focus to specializing in orexin therapies that target neurological and neuropsychiatric disorders.
The New Era Under Dr. Accardi
Dr. Accardi, who is recognized as the founder of Centessa’s Orexin Program, replaces Saurabh Saha, who will now serve as an advisor to the CEO. Francesco De Rubertis, Chair of Centessa’s Board, expressed confidence in Dr. Accardi's capabilities, emphasizing that his deep understanding of orexin biology and visionary approach aligns perfectly with the company’s mission. Dr. Saha's leadership has been pivotal in laying a robust foundation, guiding the company through its formative stages and significant milestones in drug development.
Reflections on Leadership Transition
Dr. Saha shared his thoughts on the leadership change, indicating that the time is right for such a transition as Centessa stands on the brink of a new chapter focusing solely on orexin therapeutics. He acknowledged Dr. Accardi as the right person to lead the company forward, particularly due to his integral role in developing the OX2R agonist program.
Centessa’s Focus on OX2R Agonists
Under Dr. Accardi’s leadership, Centessa aims to capitalize on the growth opportunities presented by OX2R agonists in the neuroscience space. The company’s flagship candidate, ORX750, has shown promising results in treating narcolepsy and idiopathic hypersomnia, with the registrational program slated to start in early 2026. Additionally, Centessa is progressing with other investigational compounds like ORX142 and ORX489, aimed at addressing various neurodegenerative and neuropsychiatric conditions.
Advancing the Orexin Pipeline
Dr. Accardi has a rich background in neuroscience and has previously led Orexia Therapeutics, where he successfully acquired substantial funding and strategically positioned the company for growth before its acquisition by Centessa. His educational qualifications make him well-suited for the CEO role, holding a Postgraduate in Genomic Medicine and a PhD in Biomedical Engineering.
The Promise of Orexin Therapies
Orexins are neuropeptides integral to regulating the sleep-wake cycle, and innovations in this field could address issues such as excessive daytime sleepiness, impaired cognitive function, and various fatigue-related disorders. Centessa is at the forefront of developing these OX2R agonists, exploring their therapeutic potential to transform treatment landscapes for patients battling neurological challenges.
Research & Development Focus
Ongoing clinical trials, including the Phase 2a CRYSTAL-1 study for ORX750, aim to verify the efficacy and safety of Centessa’s drug candidates. The commitment to developing transformative medicines remains strong, with a clear vision for the future enriched by Dr. Accardi's leadership.
About Centessa Pharmaceuticals
Centessa Pharmaceuticals is a clinical-stage pharmaceutical entity dedicated to discovering and bringing to market groundbreaking medicines aimed primarily at neurological disorders. With a promising pipeline centered on orexin therapies, Centessa continues to pave the way for patients in need of effective treatment options. Investors and stakeholders looking for more information can reach out via email or visit Centessa’s official website, where updates about ongoing and future programs can also be found.
Frequently Asked Questions
Who has been appointed as the new CEO of Centessa Pharmaceuticals?
Dr. Mario Alberto Accardi has been appointed as the new CEO of Centessa Pharmaceuticals.
What position does Saurabh Saha take after the leadership change?
Saurabh Saha will remain with the company as an advisor to the CEO following his transition from CEO.
What are some key products Centessa is focusing on?
Centessa is focusing on OX2R agonists, particularly ORX750, ORX142, and ORX489, targeting various neurological and sleep-wake disorders.
What is the purpose of the OX2R agonist program?
The OX2R agonist program is designed to address excessive daytime sleepiness, cognitive deficits, and fatigue associated with several neurological disorders.
How can investors contact Centessa Pharmaceuticals?
Investors can contact Centessa Pharmaceuticals through Kristen K. Sheppard, SVP of Investor Relations, at investors@centessa.com.
